Intensifying insulin treatment: Options, practical issues, and the role of the nurse practitioner

Journal of the American Academy of Nurse Practitioners

Volumn 24, Issue SUPPL.1, 2012, Pages 260-269

  Kruger, Davida F ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Insulin therapy; Patient education; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ARTICLE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NURSE ATTITUDE; NURSE PRACTITIONER; NURSING; PATIENT EDUCATION;

DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; NURSE PRACTITIONERS; NURSE'S ROLE; PATIENT EDUCATION AS TOPIC;

EID: 84860658166     PISSN: 10412972     EISSN: 17457599     Source Type: Journal    
DOI: 10.1111/j.1745-7599.2012.00724.x     Document Type: Article

References (65)

1. Arts, E. E., Landewe-Cleuren, S. A., Schaper, N. C., & Vrijhoef, H. J. (2011). The cost-effectiveness of substituting physicians with diabetes nurse specialists: A randomized controlled trial with 2-year follow-up. Journal of Advanced Nursing, DOI:
2. Banerjee, M., Macdougall, M., & Lakhdar, A. F. (2011). Impact of a single one to one education on glycaemic control in patients with diabetes. Journal of Diabetes, DOI:
3. Barnett, A. H. (2004). Treating to goal: Challenges of current management. European Journal of Endocrinology, 151, T3-T7.
4. Bartol, T. (2012). Improving the treatment experience for patients with type 2 diabetes: Role of the nurse practitioner. Journal of the American Academy of Nurse Practitioners, 24(Suppl.), 270-276.
5. Brez, S., Rowan, M., Malcolm, J., Izzi, S., Maranger, J., Liddy, C., ... & Ooi, T. C. (2009). Transition from specialist to primary diabetes care: A qualitative study of perspectives of primary care physicians. Biomed Central Family Practice, 10, 1-8.
6. Brown, J. B., & Nichols, G. A. (2003). Slow response to loss of glycemic control in type 2 diabetes mellitus. American Journal of Managed Care, 9, 213-217.
7. Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y., ... & Rosenstock, J. (2011). Use of twice daily exenatide in basal insulin treated patients with type 2 diabetes. Annals of Internal Medicine, 154, 103-112.
8. Calvert, M. J., McManus, L. J., & Freemantle, N. (2007). Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: Retrospective cohort study. British Journal of General Practice, 54, 455-460.
9. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association. (2008). Clinical Practice guidelines for the prevention and management of diabetes in Canada. Canadian Journal of Diabetes, 32(Suppl. 1), S1-S201.
10. Chapman, T. M., Noble, S., & Goa, K. L. (2002). Insulin aspart: A review of its use in the management of type 1 and 2 diabetes mellitus. Drugs, 62, 1945-1981. Erratum in 2003, 63, 512.
11. Coates, P. A., Ollerton, R. L., Luzio, S. D., Ismail, I., & Owens, D. R. (1994). A glimpse of the 'natural history' of established type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis. Diabetes Research and Clinical Practice, 26, 177-187.
12. Conlon, P. C. (2011). A practical approach to type 2 diabetes. Nursing Clinics of North America, 36, 193-202.
13. Cuddihy, R. M., Philis-Tsimikas, A., & Nazeri, A. (2011). Type 2 diabetes care and insulin intensification: Is a more multidisciplinary approach needed? Results from the MODIFY survey. Diabetes Educator, 37, 111-123.
14. Dale, J., Martin, S., & Gadsby, R. (2010). Insulin initiation in primary care for patients with type 2 diabetes: 3-year follow-up study. Primary Care Diabetes, 4, 85-89.
15. Dancer, S, & Courtney, M. (2010). Improving diabetes patient outcomes: Framing research into the chronic care model. Journal of the American Academy of Nurse Practitioners, 22, 580-585.
16. Davidson, J. A., Liebl, A., Christiansen, J. S., Fulcher, G., Ligthelm, R. J., Brown, P., ... & Kawamori, R. (2009). Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: A meta-analysis. Clinical Therapeutics, 31, 1641-1651.
17. Derr, R., Garrett, E., Stacy, G.A., & Saudek, C. D. (2003). Is HbA1c affected by glycemic instability Diabetes Care, 26, 2728-2733.
18. Edelman, S. V., Bode, B. W., Bailey, T. S., Kipnes, M. S., Brunelle, R., Chen, X., & Frias, J. P. (2010). Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen. Diabetes Technology and Therapeutics, 12, 627-633.
19. Gagliardino, J. J, Aschner, P., Baik, S. H., Chan, J., Chantelot, J. M., Ilkova, H., & Ramachandran, A; IDMPS investigators. (2011). Patients' education, and its impact on care outcomes, resource consumption and working conditions: Data from the International Diabetes Management Practices Study (IDMPS). Diabetes & Metabolism, DOI:
20. Handelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., ... & Wyne, K. L; AACE Task Force for Developing a Diabetes Comprehensive Care Plan. (2011). American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: Executive summary. Endocrine Practice, 17, 287-302.
21. Harris, S. B., Kapor, J., Lank, C. N., Willan, A. R., & Houston, T. (2010). Clinical inertia in patients with T2DM requiring insulin in family practice. Canadian Family Physician, 56, e418-e424.
22. Heise, T., & Pieber, T. R. (2007). Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes, Obesity & Metabolism, 9, 648-659.
23. Hirsch, I. B., Bergenstal, R. M., Parkin, C. G., Wright, E., Jr., & Buse, J. B. (2005). A real world approach to insulin therapy in primary care practice. Clinical Diabetes, 23, 78-86.
24. Hirsch, I. B., & Brownlee, M. (2005). Should minimal blood glucose variability become the gold standard of glycemic control Journal of Diabetes and its Complications, 19, 178-181.
25. Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K.; 4-T Study Group. (2009). Three-year efficacy of complex insulin regimens in type 2 diabetes. New England Journal of Medicine, 361, 1736-1747. Erratum in 2010, 363, 2078.
26. Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. (2008). 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine, 359, 1577-1589.
27. Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C.; 4-T Study Group. (2007). Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. New England Journal of Medicine, 357, 1716-1730.
28. Garber, A. J., Wahlen, J., Wahl, T., Bressler, P., Braceras, R., Allen, E., & Jain, R. (2006). Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes, Obesity & Metabolism, 8, 58-66.
29. Jacobsen, L. V., Søgaard, B., & Riis, A. (2000). Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. European Journal of Clinical Pharmacology, 56, 399-403.
30. Jenkins, N., Hallowell, N., Farmer, A. J., Holman, R. R., & Lawton, J. (2011). Participants' experience of intensifying insulin therapy during the Treating to Target in Type 2 diabetes (4-T) Trial: Qualitative interview study. Diabetic Medicine, 28, 543-548.
31. Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2006). The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care, 29, 1486-1490.
32. King, A. B. (2010). No higher dose requirements with insulin detemir than glargine in type 2 diabetes: A crossover, double-blind, and randomized study using continuous glucose monitoring. Journal of Diabetes Science and Technology, 4, 151-154.
33. Lankisch, M. R., Ferlinz, K. C., Leahy, J. L., & Scherbaum, W. A.; Orals Plus Apidra and LANTUS (OPAL) study group. (2008). Introducing a simplified approach to insulin therapy in type 2 diabetes: A comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes, Obesity & Metabolism, 10, 1178-1185. Erratum in 2010, 12, 461.
34. Liebl, A., Prager, R., Binz, K., Kaiser, M., Bergenstal, R., & Gallwitz, B.; PREFER Study Group. (2009). Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER study. A randomised controlled trial. Diabetes, Obesity & Metabolism, 11, 45-52.
35. Ligthelm, R. J., Gylvin, T., DeLuzio, T., & Raskin, P. (2011). A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: A randomized, open-label study. Endocrine Practice, 17, 41-50.
36. Massi-Benedetti, M. (2006). Changing targets in the treatment of type 2 diabetes. Current Medical Research and Opinion, 22(Suppl. 2), S5-S13.
37. Meneghini, L., Mersebach, H., Kumar, S., Svendsen, A. L., & Hermansen, K. (2011). Comparison of two intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: The STEP-Wise™ randomized study. Endocrine Practice, 17, 727-736.
38. Monami, M., Marchionni, N., & Mannucci, E. (2008). Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: A meta-analysis. Diabetes Research and Clinical Practice, 81, 184-189.
39. Monami, M., Marchionni, N., & Mannucci, E. (2009). Long-acting insulin analogues vs NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes, Obesity & Metabolism, 11, 372-378.
40. Monnier, L., & Colette, C. (2008). Glycemic variability. Should we and can we prevent it Diabetes Care, 31(Suppl. 2), S150-S154.
41. Monnier, L., Colette, C., & Owens, D. R. (2008). Glycemic variability: The third component of the dysglycemia in diabetes. Is it Important? How to Measure it? Journal of Diabetes Science and Technology, 2, 1094-1100.
42. Monnier, L., Lapinski, H., & Colette, C. (2003). Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hypoglycaemia of type 2 diabetes patients. Diabetes Care, 26, 881-885.
43. Mundinger, M. O., Kane, R. L., Lenz, E. R., Totten, A. M., Tsai, W. Y., Cleary, P. D., ... & Shelanski, M. L. (2000). Primary care outcomes in patients treated by nurse practitioners or physicians: A randomized trial. Journal of the American Medical Association, 283, 59-68.
44. Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B.; American Diabetes Association; European Association for Study of Diabetes. (2009). Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 32, 193-203.
45. Nichols, G. A., Koo, Y. H., & Shah, S. N. (2007). Delay of insulin addition to oral combination therapy despite inadequate glycemic control: Delay of insulin therapy. Journal of General Internal Medicine, 22, 453-458.
46. Niskanen, L., Virkamaki, A., Hansen, J. B., & Saukkonen, T. (2009). Fasting plasma glucose variability as a marker of nocturnal hypoglycaemia in diabetes: Evidence from the PREDICTIVE study. Diabetes Research and Clinical Practice, 86, e15-e18.
47. Ohman-Strickland, P. A., Orzano, A. J., Hudson, S. V., Solberg, L. I., DiCiccio-Bloom, B., O'Malley, D., ... & Crabtree, B. F. (2008). Quality of diabetes care in family medicine practices: Influence of nurse-practitioners and physician's assistants. Annals of Family Medicine, 6, 14-22.
48. Peyrot, M., Rubin, R. R., Lauritzen, T., Skovlund, S. E., Snoek, F. J., Matthews, D. R., ... & Kleinebreil, L.; International DAWN Advisory Panel. (2005). Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care, 28, 2673-2679.
49. Pozzilli, P., Leslie, R.D., Chan, J., De Fronzo, R., Monnier, L., Raz, I., & Del Prato, S. (2010). The A1C and ABCD of glycaemia management in type 2 diabetes: A physician's personalized approach. Diabetes/Metabolism Research and Reviews, 26, 239-244.
50. Raskin, P., Gylvin, T., Weng, W., & Chaykin, L. (2009). Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled, clinical study in patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 25, 542-548.
51. Redman, B. K. (2007). Responsibility for control; ethics of patient preparation for self-management of chronic disease. Bioethics, 21, 243-250.
52. Riddle, M., Pencek, R., Charenkavanich, S., Lutz, K., Wilhelm, K., & Porter, L. (2009). Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care, 32, 1577-1582.
53. Rodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., ... & Schwartz, S. S. (2009). Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocrine Practice, 15, 540-559.
54. Rosenstock, J., Davies, M., Home, P. D., Larsen, J., Koenen, C., & Schernthaner, G. (2008). A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia, 51, 408-416.
55. Rothman, R. L., DeWalt, D. A., Malone, R., Bryant, B., Shintani, A., Crigler, B., ... & Pignone, M. (2004). Influence of patient literacy on the effectiveness of a primary care-based diabetes disease management program. Journal of the American Medical Association, 292, 1711-1716.
56. Rubino, A., McQuay, L. J., Gough, S. C., Kvasz, M., & Tennis, P. (2007). Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: A population based analysis in the UK. Diabetic Medicine, 24, 1412-1418.
57. Sarkar, U., Piette, J. D., Gonzales, R., Lessler, D., Chew, L. D., Reilly, B., ...& Schillinger, D. (2008). Preferences for self-management support: Findings from a survey of diabetes patients in safety-net health systems. Patient Education and Counseling, 70, 102-110.
58. Singh-Franco, D., Perez, A., & Harrington, C. (2011). The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: A systematic review and meta-analysis. Diabetes, Obesity & Metabolism, 13, 169-180.
59. Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A., ... & Sherwin, R. S.; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. (2009). Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. Journal of the American College of Cardiology, 53, 298-304.
60. Spollett, G. (2012). Insulin initiation in type 2 diabetes: What are the treatment regimen options and how can we best help patients feel empowered? Journal of the American Academy of Nurse Practitioners, 24(Suppl.), 249-259.
61. Stratton, I. M., Adler, A. I., Neil, H. A., Matthews, D. R., Manley, S. E., Cull, C. A., ... & Holman, R. R. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. British Medical Journal, 321, 405-412.
62. Unnikrishnan, A. G., Tibaldi, J., Hadley-Brown, M., Krentz, A. J., Ligthelm, R., Damci, T., ... & Raz, I. (2009). Practical guidance on intensification of insulin therapy with BIAsp 30: A consensus statement. International Journal of Clinical Practice, 63, 1571-1577.
63. Vijan, S., Hayward, R. A., Ronis, D. L., & Hofer, T. P. (2005). Brief report: The burden of diabetes therapy: Implications for the design of effective patient-centered treatment regimens. Journal of General Internal Medicine, 20, 479-482.
64. Von dem Knesebeck, O., Gerstenberger, E., Link, C., Marceau, L., Roland, M., Campbell, S., ... & McKinlay, J. (2010). Differences in the diagnosis and management of type 2 diabetes in 3 countries (US, UK, and Germany): Results from a factorial experiment. Medical Care, 48, 321-326.
65. Watts, S. A., Gee, J., O'Day, M. E., Schaub, K., Lawrence, R., Aron, D., & Kirsh, S. (2009). Nurse practitioner-led multidisciplinary teams to improve chronic illness care: The unique strengths of nurse practitioners applied to shared medical appointments/group visits. Journal of the American Academy of Nurse Practitioners, 21, 167-1672.